To evaluate the pharmacologic effect of DNA-PK inhibition in tumor models, the DNA-PK kinase inhibitor ZL-2201 was developed (Fig. 1A; Supplementary Fig. S1) the ability of ZL-2201 to inhibit the enzymatic activity of DNA-PK was examined in vitro. This evidence concerns the gene PRKDC and neoplasm.